Cargando…

Thrombospondin1 as a potential therapeutic target for human nonalcoholic fatty liver disease

Detalles Bibliográficos
Autores principales:	Song, Yongfeng, Gao, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372141/ https://www.ncbi.nlm.nih.gov/pubmed/32697967 http://dx.doi.org/10.1016/j.ebiom.2020.102888

Ejemplares similares

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
por: Targher, Giovanni
Publicado: (2020)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
por: Colak, Yasar, et al.
Publicado: (2011)

Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
por: Dibba, Pratima, et al.
Publicado: (2019)

Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
por: Huang, Xiaojing, et al.
Publicado: (2023)

Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease
por: Lin, Chuan-Hao, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome: A Race Against the Clock
por: Huffman, Alexandra M, et al.
Publicado: (2022)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans
por: Inzaugarat, María Eugenia, et al.
Publicado: (2017)

Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
por: Sousa-Lima, Inês, et al.
Publicado: (2021)

Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018)

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
por: Raptis, Dimitrios D, et al.
Publicado: (2023)

Metabolic Targets in Nonalcoholic Fatty Liver Disease
por: Esler, William P., et al.
Publicado: (2019)

Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease
por: Durazzo, Marilena, et al.
Publicado: (2012)

The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease
por: Zhu, Xiaopeng, et al.
Publicado: (2016)

Is a low‐carbohydrate, high‐fat diet feasible for people with type 2 diabetes and nonalcoholic fatty liver disease?
por: Yen, Fu‐Shun, et al.
Publicado: (2023)

mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease
por: Feng, Jiayao, et al.
Publicado: (2022)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

The lipidome in nonalcoholic fatty liver disease: actionable targets
por: Pirola, Carlos J., et al.
Publicado: (2021)

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
por: Huang, Yue Ye, et al.
Publicado: (2013)

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications
por: Andronescu, Craita Isabela, et al.
Publicado: (2018)

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
por: Yu, Yao, et al.
Publicado: (2018)

Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease
por: Mijangos-Trejo, Alejandra, et al.
Publicado: (2023)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease
por: Bertran, Laia, et al.
Publicado: (2021)

Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
por: Chang, Xinxia, et al.
Publicado: (2016)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases
por: Zhang, Daqing, et al.
Publicado: (2023)

Update on Berberine in Nonalcoholic Fatty Liver Disease
por: Liu, Yang, et al.
Publicado: (2013)

G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment
por: Yang, Ming, et al.
Publicado: (2021)

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
por: Marchisello, Simona, et al.
Publicado: (2019)

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications
por: Kizivat, Tomislav, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
por: Sotiropoulou, Maria, et al.
Publicado: (2021)

Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease
por: Zhou, Run, et al.
Publicado: (2023)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease
por: Gwag, Taesik, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
por: Gusdon, Aaron M., et al.
Publicado: (2014)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i1ukrdf7b73tvj7ineq4gpsnmv